Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

A large-scale genomic study published February 19 in Science has produced the first comprehensive map of the feline ...

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has identified new molecular glue degrader compounds acting as proto-oncogene Vav (VAV1)/protein cereblon (CRBN) interaction inducers ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia Eighty patients (60% BRAFi-exposed)—63 with colorectal cancer (CRC), 13 with melanoma, and 4 with other ...

Add Yahoo as a preferred source to see more of our stories on Google. Bishop: ‘infatuation’ with science, as well as with words and language - Science History Images/Alamy Michael Bishop, who has died ...

Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.

Introduction: Medullary thyroid carcinoma is a rare cancer that originates in parafollicular C cells and can be sporadic or hereditary. Both sporadic and hereditary diseases are primarily caused by ...

A team from CNIO and CIEMAT eliminates cells that contain excessive copies of oncogenes using CRISPR gene editing. In cellular and animal models of neuroblastoma, small cell lung cancer and colon ...

1Memorial Sloan Kettering Cancer Center, New York, NY.